Updated Jul 16, 2026
Haas Jason has filed 3 SEC Form 4 filings across 2 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $20K. Lifetime open-market sales: $1.68M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-16 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale | 3.5K | $256.08 | $886K |
| 2026-06-16 | LGND | LIGAND PHARMACEUTICALS INC | S — Open-market sale | 3.0K | $255.01 | $765K |
| 2026-06-16 | LGND | LIGAND PHARMACEUTICALS INC | M — Option exercise | 1.0K | $51.56 | $52K |
| 2026-06-16 | LGND | LIGAND PHARMACEUTICALS INC | M — Option exercise | 3.0K | $51.56 | $155K |
| 2026-06-09 | LGND | LIGAND PHARMACEUTICALS INC | A — Grant or award | 836 | $0.00 | |
| 2026-05-12 | ODTX | Odyssey Therapeutics, Inc. | P — Open-market purchase | 1.0K | $20.00 | $20K |
| 2024-11-20 | SYRS | Syros Pharmaceuticals, Inc. | S — Open-market sale | 137.8K | $0.21 | $29K |
| 2024-11-04 | SYRS | Syros Pharmaceuticals, Inc. | F — Tax withholding / forfeiture | 5.6K | $2.09 | $12K |
| 2024-11-04 | SYRS | Syros Pharmaceuticals, Inc. | M — Option exercise | 18.9K | — |
Haas Jason is a corporate insider — currently tracked as Director of LIGAND PHARMACEUTICALS INC (LGND). InsiderAlpha tracks every SEC Form 4 filing in real time.
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 1 open-market purchases ($20K) and 3 open-market sales ($1.68M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Haas Jason profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.